Skip to content

Molecular Pharmacology (USA) Ltd.: 10-Q filed 2014-02-11

What Molecular Pharmacology (USA) Ltd. reported in its quarterly report filed 2014-02-11 (fiscal Q2 2014): 15 published measures, 47 facts as tagged in accession 0001221508-14-000003.

This filing

Form
10-Q (quarterly report)
Filed
2014-02-11
Fiscal period
fiscal Q2 2014
Accession
0001221508-14-000003 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Molecular Pharmacology (USA) Ltd. filings.

Reported measures

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2013-12-312,072,461USD
At 2013-06-302,066,129USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2013-12-31-2,062,881USD
At 2013-06-30-2,053,873USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2013-12-314,997USD
At 2013-06-307,046USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2013-10-01 to 2013-12-31-22,554USD92
2013-07-01 to 2013-12-31-63,327USD184
2004-07-14 to 2013-12-31-2,125,275USD3458
2012-10-01 to 2012-12-31-48,897USD92
2012-07-01 to 2012-12-31-100,993USD184

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2013-10-01 to 2013-12-31-35,503USD92
2013-07-01 to 2013-12-31-63,846USD184
2004-07-14 to 2013-12-31-2,145,439USD3458
2012-10-01 to 2012-12-31-59,779USD92
2012-07-01 to 2012-12-31-114,479USD184

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2013-10-01 to 2013-12-31-60,250USD92
2013-07-01 to 2013-12-317,478USD184
2004-07-14 to 2013-12-312,278,268USD3458
2012-10-01 to 2012-12-3156,159USD92
2012-07-01 to 2012-12-31150,664USD184

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2013-12-31-2,125,275USD
At 2013-06-30-2,061,948USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2013-10-01 to 2013-12-31-22,554USD92
2013-07-01 to 2013-12-31-63,327USD184
2004-07-14 to 2013-12-31-2,409,423USD3458
2012-10-01 to 2012-12-31-48,074USD92
2012-07-01 to 2012-12-31-100,170USD184

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2013-12-319,580USD
At 2013-06-3012,256USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2013-12-3120,482USD
At 2013-06-3021,628USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2013-12-31106,707USD
At 2013-06-30106,707USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2013-12-31118USD
At 2013-06-30140USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2013-10-01 to 2013-12-3171,046USD92
2013-07-01 to 2013-12-31-9,008USD184
2004-07-14 to 2013-12-31-2,281,142USD3458
2012-10-01 to 2012-12-31-50,726USD92
2012-07-01 to 2012-12-31-133,756USD184

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2013-10-01 to 2013-12-3111USD92
2013-07-01 to 2013-12-3122USD184
2004-07-14 to 2013-12-316,909USD3458
2012-10-01 to 2012-12-3184USD92
2012-07-01 to 2012-12-31170USD184

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2004-07-14 to 2013-12-31234,497USD3458

Inspect the source

Entity
Molecular Pharmacology (USA) Ltd. / CIK 0001191357
Captured
SEC response SHA-256
73b33a10759d23c7619f4a45effaa7324586af6c4aaef444b5495efc1f125e84

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001191357.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))